← FDA DRUG APPROVALS

FDA ANDA · ANDA206006

LANSOPRAZOLE, AMOXICILLIN, CLARITHROMYCIN

Sponsor: RISING

APPLICATION
ANDA206006
TYPE
ANDA
ORIGINAL APPROVAL
2016-10-07
LATEST ACTION
2024-06-12
ROUTE
ORAL
DOSAGE FORM
CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS
MARKETING STATUS
Prescription

Products

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)Prescription
AMOXICILLIN 500MG, CLARITHROMYCIN 500MG, LANSOPRAZOLE 30MG · CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS · ORAL

Approval history

2024-06-12Labeling · Supplement 9 · standardAP
2024-06-11Labeling · Supplement 8 · standardAP
2023-08-16Labeling · Supplement 7 · standardAP
2023-07-18Labeling · Supplement 6 · standardAP
2022-04-14Labeling · Supplement 4 · standardAP
2022-03-04Labeling · Supplement 3 · standardAP
2022-03-04Labeling · Supplement 2 · standardAP
2016-10-07UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →